How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

22,197 results for

Insulin Dosing

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Issues and Ideas in Bolus Advisor Research With Commentary on “A Methodology to Compare Insulin Dosing Algorithms in Real-Life Settings” Full Text available with Trip Pro

Issues and Ideas in Bolus Advisor Research With Commentary on “A Methodology to Compare Insulin Dosing Algorithms in Real-Life Settings” The accompanying article by Groat et al in this issue presents a methodology to compare glucose outcomes from insulin bolus dose recommendations observed retrospectively from a novel iDecide bolus calculator with glucose outcomes from the prospective bolus recommendations provided by a current insulin pump. The methodology in this article evaluates a bolus (...) merits serious consideration, yet the actual dose recommendations provided by the iDecide calculator introduce wider lessons on how bolus calculator glucose outcomes might be better optimized.

2017 Journal of diabetes science and technology

122. Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems Full Text available with Trip Pro

Bolus Insulin Dose Error Distributions Based on Results From Two Clinical Trials Comparing Blood Glucose Monitoring Systems In 2 previous clinical trials, fingertip capillary blood samples were evaluated using prespecified blood glucose monitoring systems (BGMSs) and a reference YSI glucose analyzer. In post hoc analyses, hypothetical insulin doses were calculated using these blood glucose measurements; dosing errors were compared for each trial.For each blood glucose measurement, premeal bolus (...) insulin dosing was determined for a hypothetical person, assuming a 60-g carbohydrate meal and 100-mg/dL target blood glucose level (adjusting 1/25 insulin sensitivity and 1/15 insulin:carbohydrate ratio inputs to account for BGMS measurement error). Dosing error was the difference between doses calculated using the BGMS and YSI results.In Clinical Trial 1, 95% dose error ranges (in units of insulin) were: CONTOUR®NEXT EZ BGMS (EZ), -0.9 to 0.5; Accu-Chek® Aviva BGMS (ACA), -0.5 to 1.8; FreeStyle

2017 Journal of diabetes science and technology

123. The Safety of Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Still Not Resolved Full Text available with Trip Pro

The Safety of Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Still Not Resolved 28420260 2018 11 13 1932-2968 11 4 2017 07 Journal of diabetes science and technology J Diabetes Sci Technol The Safety of Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Still Not Resolved. 856-857 10.1177/1932296817704446 Shapiro Alan R AR 1 Department of Medicine, New York University School of Medicine, New York, NY, USA. eng Letter 2017 04 18 United States J Diabetes

2017 Journal of diabetes science and technology

124. A systematic review of insulin dosing strategies used for dietary fat and a combination of dietary fat and protein in Type 1 Diabetes

A systematic review of insulin dosing strategies used for dietary fat and a combination of dietary fat and protein in Type 1 Diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) , duration of ischemia and duration of reperfusion (if applicable). ">Data to be extracted: animal model Example: Dose, timing of administration, frequency of administration, route of administration, vehicle. ">Data to be extracted: intervention of interest Example: Serum creatinine; continuous; umol/L (may be recalculated from mg/dL). ">Data to be extracted: primary outcome(s) Example: Blood urea nitrogen; continuous; mmol/L (may be recalculated from mg/dL); Renal histological damage as assessed

2019 PROSPERO

125. Exercise dose for improving insulin sensitivity and in overweight or obese older adults, evaluated in clinical trials

Exercise dose for improving insulin sensitivity and in overweight or obese older adults, evaluated in clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) of reperfusion (if applicable). ">Data to be extracted: animal model Example: Dose, timing of administration, frequency of administration, route of administration, vehicle. ">Data to be extracted: intervention of interest Example: Serum creatinine; continuous; umol/L (may be recalculated from mg/dL). ">Data to be extracted: primary outcome(s) Example: Blood urea nitrogen; continuous; mmol/L (may be recalculated from mg/dL); Renal histological damage as assessed by Jablonski scale; continuous; Jablonski score

2019 PROSPERO

126. Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03053089 Recruitment Status : Completed First Posted : February 14, 2017

2017 Clinical Trials

127. Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment

, dose adjustment, and prevention for hypoglycemia and provided at-home measurement device at Visit 1 for screening. Subjects will receive instructions to check daily glucose levels by home glucose meter, to record insulin regimen and dose, the hypoglycemia diary if blood glucose <70 mg/dL or a hypoglycemic event occurs in the apps, and to synchronize data for automatically transferring to system. Subjects who synchronized their information more than once during 1 week of run-in period (...) to see a doctor during Week 1-12. The unscheduled visit to clinic is also allowed to the subjects who have difficulty in insulin dose adjustment despite of two or more unscheduled tele-visit. However, even if this criterion does not apply, patients who initiate insulin or change their regimen (eg, from basal insulin once daily to premixed insulin or multiple dose insulin injections) will be allowed to have additional planned doctor visits prior to Visit 3, which is not included in the unscheduled

2017 Clinical Trials

128. Dapagliflozin in Patients with Type 1 Diabetes: A post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a Phase IIa pilot study. (Abstract)

Dapagliflozin in Patients with Type 1 Diabetes: A post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a Phase IIa pilot study. To investigate the effects of total daily insulin dose (TDD) reductions on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate (a marker for diabetic ketosis/ketoacidosis [DKA]) levels, using patient-level data from a 14-day, pilot study (...) of dapagliflozin in type 1 diabetes (T1DM).A post hoc exploratory correlation analysis was performed to determine the relationship between change in TDD and (1) 24-hour mean glucose, assessed by continuous glucose monitoring, and (2) fasting β-hydroxybutyrate, in 70 patients with T1DM receiving insulin and dapagliflozin (1, 2.5, 5 or 10 mg) or placebo. The pharmacodynamic effect of dapagliflozin was estimated as a virtual "insulin dose" using 24-hour urinary glucose excretion values and a recognized insulin

2017 obesity & metabolism

129. A Randomized Controlled Study of an Insulin Dosing Application That Uses Recognition and Meal Bolus Estimations. Full Text available with Trip Pro

A Randomized Controlled Study of an Insulin Dosing Application That Uses Recognition and Meal Bolus Estimations. Throughout the insulin pump therapy, decisions of prandial boluses programming are taken by patients individually a few times every day, and, moreover, this complex process requires numerical skills and knowledge in nutrition components estimation. The aim of the study was to determine the impact of the expert system, supporting the patient's decision on meal bolus programming (...) requirement in both groups was comparable-the average difference in total daily insulin dose between two groups was 0.26 (SD 7.06 IU, P = .9).The expert system in meal insulin dosing allows improvement in glucose control without increasing the rates of hypoglycemia or the insulin requirement.

2017 Journal of diabetes science and technology Controlled trial quality: uncertain

130. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus. Full Text available with Trip Pro

Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus. BACKGROUND Although the efficacy of combination therapy consisting of basal insulin and oral hypoglycemic agents (OHAs) has been shown, which OHAs are the most efficient remains unclear. MATERIAL AND METHODS Five patients with type 2 diabetes were enrolled and treated (...) with insulin degludec and metformin as a basal therapy. The patients were randomized in a cross-over fashion to receive a combination of mitiglinide (10 mg) and voglibose (0.2 mg) (M+V) 3 times daily or linagliptin (5 mg) (L) once daily for 8 weeks. After 8 weeks, 2 kinds of meal tolerance tests were performed as breakfast on 2 consecutive days. The first breakfast contained 460 kcal (carbohydrates, 49.1%; protein, 15.7%; fat, 35.2%), while the second contained 462 kcal (carbohydrates, 37.2%; protein, 19.6

2017 Medical science monitor basic research Controlled trial quality: uncertain

131. Impact of ELKa, the Electronic Device for Prandial Insulin Dose Calculation, on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus: A Randomized Controlled Trial. Full Text available with Trip Pro

Impact of ELKa, the Electronic Device for Prandial Insulin Dose Calculation, on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus: A Randomized Controlled Trial. Background. The ELKa system is composed of computer software, with a database of nutrients, and a dedicated USB kitchen scale. It was designed to automatize the everyday calculations of food exchanges and prandial insulin doses. Aim. To investigate the influence of the ELKa on metabolic control in children (...) usage for >50% of meals achieved lower HbA1C levels (P = 0.002), lower basal insulin amounts (P = 0.049), and lower intrasubject standard deviation of blood glucose levels (P = 0.023) in comparison with the control. Moreover, in the intervention group, significant reduction of HbA1C level, by 0.55% point (P = 0.002), was noted. No intergroup differences were found in the hypoglycemic episodes, BMI-SDS, bolus insulin dosage, and total daily insulin dosage. Conclusions. The ELKa system improves

2017 Journal of diabetes research Controlled trial quality: uncertain

132. The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. (Abstract)

satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables. Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age. Changes in weight were only associated with liraglutide treatment, independent of all baseline (...) The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients' baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment

2017 obesity & metabolism Controlled trial quality: uncertain

133. High-strength insulins: think and act in units of insulin to prevent errors

High-strength insulins: think and act in units of insulin to prevent errors FEATURED REVIEW At home as in hospital (and other healthcare facilities), errors associated with insulin use are numerous, frequent and can have serious consequences. How can dosing errors due to the coexistence of different strengths of insulin on the market be prevented? Full review (2 pages) available for download by subscribers. Abstract The coexistence of different strengths of insulin (100 units/ml, 200 units/ml (...) and 300 units/ml) on the market can lead to dosing errors, sometimes with serious consequences. These errors are due to: attempts at dose conversion that are actually unnecessary; prescribing errors; use of an insulin syringe to draw up solution from a pen cartridge; and differences between pens in the number of units of insulin per dose step. When selecting the dose on an insulin pen, the number displayed on the dose counter always corresponds to the number of units of insulin to be administered

2019 Prescrire

134. Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®) The safety and scientific validity of this study

2012 Clinical Trials

135. Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria : Male or female patients, between 18 and 65 years of age, inclusive, with diabetes mellitus type 1 for more than one year, as defined by the American Diabetes Association. Total insulin dose of <1.0 U/kg/day. Body weight between 50.0 and 95 kg, inclusive, body mass index between 18.5 and 29 kg/m², inclusive. Fasting serum C-peptide <0.3 nmol/L. Glycohemoglobin (HbA1c) ≤75 mmol/mol (≤9%). Stable insulin regimen for at least 2 (...) Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2015 Clinical Trials

136. Insulin Dosing in Type 1 Diabetes

): 50% of total ( ) once daily or twice daily (rapid acting): 50% of total Rapid acting s: , Divide out equally before meals Adjust later for carb count variations at meals IV. Management: Adjustments See for adjustment regimen Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Insulin Dosing in Type 1 Diabetes." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip (...) Insulin Dosing in Type 1 Diabetes Insulin Dosing in Type 1 Diabetes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Insulin Dosing

2018 FP Notebook

137. Insulin Dosing in Type 2 Diabetes

) ( ) ( ) ( ) Step 3: Starting dose <8 Basal 0.1 units/kg once daily AND 0.1 units/kg divided equally before meals (start before breakfast and dinner) 8-10 Basal 0.2 units/kg once daily AND 0.2 units/kg divided equally before meals (start before breakfast and dinner) >10 Basal 0.3 units/kg once daily AND 0.3 units/kg divided equally before meals (start before breakfast and dinner) VII. Protocol: Starting Basal/Bolus Insulin using NPH Background Other regimens less complicated and therefore preferred However, NPH (...) : Starting Insulin using Premixed Insulin Step 0: Adjust oral medications Stop ( , ) Continue sensitizers ( , ) preparations (for twice daily dosing) Mix 75/25 or Premix 70/30 Starting dose Based on Regimen ( Augmentation) as above Divide current basal dose into 2/3 AM and 1/3 PM or Divide current basal dose into 1/2 AM and 1/2 PM Based on current A1C <8: 0.1 units/kg in AM and 0.1 units/kg in PM A1C 8-10: 0.2 units/kg in AM and 0.2 units/kg in PM A1C >10: 0.3 units/kg in AM and 0.3 units/kg in PM

2018 FP Notebook

138. Carbohydrate Count in Insulin Dosing

Carbohydrate Count in Insulin Dosing Carbohydrate Count in Insulin Dosing Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Carbohydrate (...) Count in Insulin Dosing Carbohydrate Count in Insulin Dosing Aka: Carbohydrate Count in Insulin Dosing , Insulin Adjustment with Carbohydrate Counting From Related Chapters II. Management: Step 1a - Determine Carbohydrate to Insulin ratio Determine total used per day Option 1: Known dose from multiple daily doses or Option 2: Calculate based on patient weight Type I: Total daily (TDI) TDI = WtKg x 0.1 to 0.3 units/kg (start low) Type I: Total basal dose (TBD) TBD = WtKg x 0.2 TBD = 0.4 x Total Daily

2018 FP Notebook

139. Insulin Dosing

Insulin Dosing Insulin Dosing Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Insulin Dosing Insulin Dosing Aka: Insulin Dosing From (...) for consistent pattern in s for >3 days Compare for same time each day For each time of day: Calculate range Calculate median Consider eating and activity patterns during day Ignore spurious values Adjust only one dose at a time Correct first Correct highest s next Maintain a 50:50 mix of Basal to VI. Evaluation: Adjustment of Insulin Adjustment factors (for lows and highs) Adjust in small steps at a time Adjustment steps based on amount dose <10 units: Adjust by 1 unit dose 10-20 units: Adjust by 2 units

2018 FP Notebook

140. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Full Text available with Trip Pro

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Exposing the oral mucosa to antigen may stimulate immune tolerance. It is unknown whether treatment with oral insulin can induce a tolerogenic immune response in children genetically susceptible to type 1 diabetes.To assess the immune responses and adverse events associated with orally administered insulin in autoantibody-negative, genetically at-risk (...) children.The Pre-POINT study, a double-blind, placebo-controlled, dose-escalation, phase 1/2 clinical pilot study performed between 2009 and 2013 in Germany, Austria, the United States, and the United Kingdom and enrolling 25 islet autoantibody-negative children aged 2 to 7 years with a family history of type 1 diabetes and susceptible human leukocyte antigen class II genotypes. Follow-up was completed in August 2013.Children were randomized to receive oral insulin (n = 15) or placebo (n = 10) once daily

2015 JAMA Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>